{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:53:14Z","timestamp":1780051994539,"version":"3.53.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"DOI":"10.7759\/cureus.78575","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T23:59:11Z","timestamp":1738799951000},"source":"Crossref","is-referenced-by-count":5,"title":["A System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks"],"prefix":"10.7759","author":[{"given":"Lynn P","family":"Fadel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gigi","family":"Thao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Chitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin D","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nguyen Fricko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigita","family":"Budginas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz Carmelo","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ghatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar T","family":"Arani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Tabatabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller TD","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, et al.. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019, 30:72-130. 10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"key":"ref2","article-title":"Glucagon-like peptide-1 receptor agonists","author":"Collins L","year":"2024","unstructured":"Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu QK","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024, 15:1431292. 10.3389\/fendo.2024.1431292","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1090295","article-title":"User's guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer CF Jr","year":"2015","unstructured":"Shaefer CF Jr, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015, 127:818-826. 10.1080\/00325481.2015.1090295","journal-title":"Postgrad Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan AE","year":"2011","unstructured":"Hogan AE, Tobin AM, Ahern T, et al.. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011, 54:2745-2754. 10.1007\/s00125-011-2232-3","journal-title":"Diabetologia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert M","year":"2014","unstructured":"Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, Van Belle A, Dumoutier L. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study. Br J Dermatol. 2014, 171:155-161. 10.1111\/bjd.12886","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study","volume":"150","author":"Xu X","year":"2019","unstructured":"Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, Shao Z. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract. 2019, 150:167-173. 10.1016\/j.diabres.2019.03.002","journal-title":"Diabetes Res Clin Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.10.013","article-title":"Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes","volume":"146","author":"Nagae K","year":"2018","unstructured":"Nagae K, Uchi H, Morino-Koga S, Tanaka Y, Oda M, Furue M. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes. Diabetes Res Clin Pract. 2018, 146:155-161. 10.1016\/j.diabres.2018.10.013","journal-title":"Diabetes Res Clin Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02969-3","article-title":"Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature","volume":"316","author":"Salazar CE","year":"2024","unstructured":"Salazar CE, Patil MK, Aihie O, Cruz N, Nambudiri VE. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Arch Dermatol Res. 2024, 316:248. 10.1007\/s00403-024-02969-3","journal-title":"Arch Dermatol Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.255","article-title":"Hypersensitivity to glucagon\u2010like peptide\u20101 receptor agonists: a case of delayed urticaria\u2010like rash to dulaglutide and literature review","volume":"3","author":"Bianchi L","year":"2024","unstructured":"Bianchi L, Ali Biglu Marash S, Malatesta N, Hansel K, Tramontana M, Stingeni L. Hypersensitivity to glucagon\u2010like peptide\u20101 receptor agonists: a case of delayed urticaria\u2010like rash to dulaglutide and literature review. JEADV Clin Pract. 2024, 3:313-316. 10.1002\/jvc2.255","journal-title":"JEADV Clin Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15248","article-title":"Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: population-based cohort study","volume":"41","author":"Pradhan R","year":"2024","unstructured":"Pradhan R, Yu OH, Platt RW, Azoulay L. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: population-based cohort study. Diabet Med. 2024, 41:e15248. 10.1111\/dme.15248","journal-title":"Diabet Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814543483","article-title":"Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis","volume":"5","author":"Al-Badri MR","year":"2014","unstructured":"Al-Badri MR, Azar ST. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab. 2014, 5:34-38. 10.1177\/2042018814543483","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000530456","article-title":"Effects of liraglutide 3mg among patients living with psoriasis and obesity: beyond metabolic control?","volume":"16","author":"Nicolau Ramis J","year":"2023","unstructured":"Nicolau Ramis J, Nadal Nadal A, Sanch\u00eds P, Romano A, Pujol Calafat A, Nadal Llad\u00f3 C, Masmiquel Comas L. Effects of liraglutide 3mg among patients living with psoriasis and obesity: beyond metabolic control?. Obes Facts. 2023, 16:1-351. 10.1159\/000530456","journal-title":"Obes Facts"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi SF","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, et al.. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023, 14:1148209. 10.3389\/fimmu.2023.1148209","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-23-0017","article-title":"Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes","volume":"2023","author":"Malavazos AE","year":"2023","unstructured":"Malavazos AE, Meregalli C, Sorrentino F, et al.. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023, 2023:0017. 10.1530\/EDM-23-0017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-21-0007","article-title":"Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo G","year":"2021","unstructured":"Costanzo G, Curatolo S, Bus\u00e0 B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021, 2021:10.1530\/EDM-21-0007","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin J","year":"2023","unstructured":"Bezin J, Gouverneur A, P\u00e9nichon M, et al.. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023, 46:384-390. 10.2337\/dc22-1148","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii GA","year":"2024","unstructured":"Silverii GA, Monami M, Gallo M, et al.. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024, 26:891-900. 10.1111\/dom.15382","journal-title":"Diabetes Obes Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak B","year":"2024","unstructured":"Pasternak B, Wintzell V, Hviid A, et al.. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024, 385:e078225. 10.1136\/bmj-2023-078225","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091625","article-title":"The use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus does not increase the risk of pancreatic cancer: a U.S.-based cohort study","volume":"16","author":"Ayoub M","year":"2024","unstructured":"Ayoub M, Faris C, Juranovic T, Chela H, Daglilar E. The use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus does not increase the risk of pancreatic cancer: a U.S.-based cohort study. Cancers (Basel). 2024, 16:1625. 10.3390\/cancers16091625","journal-title":"Cancers (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner R","year":"2024","unstructured":"Dankner R, Murad H, Agay N, Olmer L, Freedman LS. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open. 2024, 7:e2350408. 10.1001\/jamanetworkopen.2023.50408","journal-title":"JAMA Netw Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000337929","article-title":"Exenatide reduces urinary transforming growth factor-\u03b21 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria","volume":"35","author":"Zhang H","year":"2013","unstructured":"Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-\u03b21 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res. 2013, 35:483-488. 10.1159\/000337929","journal-title":"Kidney Blood Press Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04214.x","article-title":"Investigation of the haemodynamic effects of exenatide in healthy male subjects","volume":"74","author":"Mendis B","year":"2012","unstructured":"Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol. 2012, 74:437-444. 10.1111\/j.1365-2125.2012.04214.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5414\/cp201361","article-title":"Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients \u2265 75 years of age with Type 2 diabetes","volume":"49","author":"Linnebjerg H","year":"2011","unstructured":"Linnebjerg H, Kothare PA, Seger M, Wolka AM, Mitchell MI. Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients \u2265 75 years of age with Type 2 diabetes. Int J Clin Pharmacol Ther. 2011, 49:99-108. 10.5414\/cp201361","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00529.2012","article-title":"Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance","volume":"304","author":"Gil-Lozano M","year":"2013","unstructured":"Gil-Lozano M, Roman\u00ed-P\u00e9rez M, Outeiri\u00f1o-Iglesias V, Vigo E, Brubaker PL, Gonz\u00e1lez-Mat\u00edas LC, Mallo F. Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. Am J Physiol Endocrinol Metab. 2013, 304:E1105-E1117. 10.1152\/ajpendo.00529.2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02084-6","article-title":"Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?","volume":"46","author":"Pugliese G","year":"2023","unstructured":"Pugliese G, de Alteriis G, Muscogiuri G, et al.. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?. J Endocrinol Invest. 2023, 46:1761-1774. 10.1007\/s40618-023-02084-6","journal-title":"J Endocrinol Invest"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031909","article-title":"Infertility improvement after medical weight loss in women and men: a review of the literature","volume":"25","author":"Pavli P","year":"2024","unstructured":"Pavli P, Triantafyllidou O, Kapantais E, Vlahos NF, Valsamakis G. Infertility improvement after medical weight loss in women and men: a review of the literature. Int J Mol Sci. 2024, 25:1909. 10.3390\/ijms25031909","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03487-4","article-title":"Effects and plasma proteomic analysis of GLP-1RA versus CPA\/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial","volume":"83","author":"Liao M","year":"2024","unstructured":"Liao M, Li X, Zhang H, et al.. Effects and plasma proteomic analysis of GLP-1RA versus CPA\/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Endocrine. 2024, 83:227-241. 10.1007\/s12020-023-03487-4","journal-title":"Endocrine"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2174\/1570161114666161221115324","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obese women with polycystic ovary syndrome","volume":"15","author":"Tzotzas T","year":"2017","unstructured":"Tzotzas T, Karras SN, Katsiki N. Glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obese women with polycystic ovary syndrome. Curr Vasc Pharmacol. 2017, 15:218-229. 10.2174\/1570161114666161221115324","journal-title":"Curr Vasc Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena H","year":"2020","unstructured":"Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020, 105:e2695-e2709. 10.1210\/clinem\/dgaa285","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmz019","article-title":"The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective","volume":"25","author":"Jensterle M","year":"2019","unstructured":"Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019, 25:504-517. 10.1093\/humupd\/dmz019","journal-title":"Hum Reprod Update"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/17455057241234530","article-title":"A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS","volume":"20","author":"Bader S","year":"2024","unstructured":"Bader S, Bhatti R, Mussa B, Abusanana S. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS. Womens Health (Lond). 2024, 20:17455057241234530. 10.1177\/17455057241234530","journal-title":"Womens Health (Lond)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study","volume":"179","author":"Salamun V","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018, 179:1-11. 10.1530\/EJE-18-0175","journal-title":"Eur J Endocrinol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2190","article-title":"Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men","volume":"90","author":"Pitteloud N","year":"2005","unstructured":"Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005, 90:2636-2641. 10.1210\/jc.2004-2190","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60010050","article-title":"Impact of GLP-1 agonists on male reproductive health-A narrative review","volume":"60","author":"Varnum AA","year":"2024","unstructured":"Varnum AA, Pozzi E, Deebel NA, Evans A, Eid N, Sadeghi-Nejad H, Ramasamy R. Impact of GLP-1 agonists on male reproductive health-A narrative review. Medicina (Kaunas). 2024, 60:50. 10.3390\/medicina60010050","journal-title":"Medicina (Kaunas)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1530\/REP-22-0136","article-title":"Glucagon-like peptide-1 promotes Leydig cell regeneration from stem cells in rats","volume":"165","author":"Li X","year":"2023","unstructured":"Li X, Chen L, Wang Y, Li H, Zhu Q, Ge RS. Glucagon-like peptide-1 promotes Leydig cell regeneration from stem cells in rats. Reproduction. 2023, 165:19-30. 10.1530\/REP-22-0136","journal-title":"Reproduction"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.389626","article-title":"Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain","volume":"19","author":"Diz-Chaves Y","year":"2024","unstructured":"Diz-Chaves Y, Maastor Z, Spuch C, Lamas JA, Gonz\u00e1lez-Mat\u00edas LC, Mallo F. Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain. Neural Regen Res. 2024, 19:1671-1677. 10.4103\/1673-5374.389626","journal-title":"Neural Regen Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study","volume":"44","author":"Vadini F","year":"2020","unstructured":"Vadini F, Simeone PG, Boccatonda A, et al.. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Int J Obes (Lond). 2020, 44:1254-1263. 10.1038\/s41366-020-0535-5","journal-title":"Int J Obes (Lond)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010065","article-title":"GLP1 receptor agonists-Effects beyond obesity and diabetes","volume":"13","author":"Wilbon SS","year":"2024","unstructured":"Wilbon SS, Kolonin MG. GLP1 receptor agonists-Effects beyond obesity and diabetes. Cells. 2024, 13:65. 10.3390\/cells13010065","journal-title":"Cells"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071584","article-title":"Dulaglutide modulates the development of tissue-infiltrating Th1\/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the central nervous system","volume":"20","author":"Chiou HC","year":"2019","unstructured":"Chiou HC, Lin MW, Hsiao PJ, et al.. Dulaglutide modulates the development of tissue-infiltrating Th1\/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the central nervous system. Int J Mol Sci. 2019, 20:1584. 10.3390\/ijms20071584","journal-title":"Int J Mol Sci"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1146960","article-title":"Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats","volume":"14","author":"Guo X","year":"2023","unstructured":"Guo X, Lei M, Zhao J, et al.. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. Front Pharmacol. 2023, 14:1146960. 10.3389\/fphar.2023.1146960","journal-title":"Front Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45487","article-title":"Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: a systematic review","volume":"15","author":"Parab P","year":"2023","unstructured":"Parab P, Chaudhary P, Mukhtar S, et al.. Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: a systematic review. Cureus. 2023, 15:e45487. 10.7759\/cureus.45487","journal-title":"Cureus"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1330936","article-title":"Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"15","author":"Chen W","year":"2024","unstructured":"Chen W, Cai P, Zou W, Fu Z. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. Front Endocrinol (Lausanne). 2024, 15:1330936. 10.3389\/fendo.2024.1330936","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.06.017","article-title":"Administration errors of compounded semaglutide reported to a poison control center-Case series","volume":"63","author":"Lambson JE","year":"2023","unstructured":"Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center-Case series. J Am Pharm Assoc. 2023, 63:1643-1645. 10.1016\/j.japh.2023.06.017","journal-title":"J Am Pharm Assoc"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"32","author":"Chen X","year":"2024","unstructured":"Chen X, Zhao P, Wang W, Guo L, Pan Q. The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis. Am J Geriatr Psychiatry. 2024, 32:117-127. 10.1016\/j.jagp.2023.08.010","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2019.0303","article-title":"Neurological manifestation of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"10","author":"Gao L","year":"2019","unstructured":"Gao L, Yu S, Cipriani A, et al.. Neurological manifestation of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. Aging Dis. 2019, 10:1311-1319. 10.14336\/AD.2019.0303","journal-title":"Aging Dis"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe T","year":"2020","unstructured":"Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al.. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020, 19:582-590. 10.1016\/S1474-4422(20)30173-3","journal-title":"Lancet Neurol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos TD","year":"2015","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2015, 11:202-230. 10.1900\/RDS.2014.11.202","journal-title":"Rev Diabet Stud"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu L","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022, 13:1043789. 10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.09.008","article-title":"A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer","volume":"98","author":"Alves C","year":"2012","unstructured":"Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012, 98:271-284. 10.1016\/j.diabres.2012.09.008","journal-title":"Diabetes Res Clin Pract"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2366","article-title":"Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies","volume":"348","author":"Li L","year":"2014","unstructured":"Li L, Shen J, Bala MM, et al.. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014, 348:g2366. 10.1136\/bmj.g2366","journal-title":"BMJ"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0482","article-title":"Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis","volume":"33","author":"Garg R","year":"2010","unstructured":"Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010, 33:2349-2354. 10.2337\/dc10-0482","journal-title":"Diabetes Care"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0075","article-title":"Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population","volume":"14","author":"Romley JA","year":"2012","unstructured":"Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther. 2012, 14:904-911. 10.1089\/dia.2012.0075","journal-title":"Diabetes Technol Ther"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0120","article-title":"Effectiveness of sitagliptin in Asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience","volume":"13","author":"Sudhakaran C","year":"2011","unstructured":"Sudhakaran C, Kishore U, Anjana RM, Unnikrishnan R, Mohan V. Effectiveness of sitagliptin in Asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience. Diabetes Technol Ther. 2011, 13:27-32. 10.1089\/dia.2010.0120","journal-title":"Diabetes Technol Ther"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise T","year":"2022","unstructured":"Heise T, Mari A, DeVries JH, et al.. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022, 10:418-429. 10.1016\/S2213-8587(22)00085-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.786732","article-title":"Corrigendum: Safety of semaglutide","volume":"12","author":"Smits MM","year":"2021","unstructured":"Smits MM, Van Raalte DH. Corrigendum: Safety of semaglutide. Front Endocrinol (Lausanne). 2021, 12:786732. 10.3389\/fendo.2021.786732","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-1124. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01556-2","article-title":"Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the\u00a0FDA Adverse Event Reporting System and literature visualization analysis","volume":"45","author":"Cao M","year":"2023","unstructured":"Cao M, Pan C, Tian Y, Wang L, Zhao Z, Zhu B. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the\u00a0FDA Adverse Event Reporting System and literature visualization analysis. Int J Clin Pharm. 2023, 45:689-697. 10.1007\/s11096-023-01556-2","journal-title":"Int J Clin Pharm"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"17","author":"Bandyopadhyay S","year":"2023","unstructured":"Bandyopadhyay S, Das S, Samajdar SS, Joshi SR. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023, 17:102849. 10.1016\/j.dsx.2023.102849","journal-title":"Diabetes Metab Syndr"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","volume":"4","author":"Ferhatbegovi\u0107 L","year":"2023","unstructured":"Ferhatbegovi\u0107 L, Mr\u0161i\u0107 D, Maci\u0107-D\u017eankovi\u0107 A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc. 2023, 4:1293926. 10.3389\/fcdhc.2023.1293926","journal-title":"Front Clin Diabetes Healthc"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01133-1","article-title":"Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis","volume":"19","author":"D'Andrea E","year":"2020","unstructured":"D'Andrea E, Kesselheim AS, Franklin JM, Jung EH, Hey SP, Patorno E. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020, 19:154. 10.1186\/s12933-020-01133-1","journal-title":"Cardiovasc Diabetol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 agonists and recent cardiovascular outcomes trials","volume":"96","author":"Sheahan KH","year":"2020","unstructured":"Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J. 2020, 96:156-161. 10.1136\/postgradmedj-2019-137186","journal-title":"Postgrad Med J"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-2232. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-1084. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx N","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022, 146:1882-1894. 10.1161\/CIRCULATIONAHA.122.059595","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/333526-a-system-based-review-on-effects-of-glucagon-like-peptide-1-receptor-agonists-benefits-vs-risks","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T23:59:14Z","timestamp":1738799954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/333526-a-system-based-review-on-effects-of-glucagon-like-peptide-1-receptor-agonists-benefits-vs-risks"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":66,"URL":"https:\/\/doi.org\/10.7759\/cureus.78575","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}